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Abstract
It is general knowledge that glycaemia is affected by digested nutrients. 
Amino acids intake appears to be an important regulator in this regard. Many 
questions need to be answered, such as the real mediators of this response 
and the mechanisms underlying this metabolic behavior. Studies have been 
undertaken in order to investigate the role of amino acids on metabolic 
parameters. Their main findings suggest that the ingestion of free amino 
acids have a pivotal role in avoiding glycaemia excursions, improving glucose 
tolerance. In parallel, several important molecules for glucose metabolism have 
been exploited. Insulin and glucagon-like peptide – 1 (GLP-1) release seem 
to be the main triggers of this response. This insulinogenic effect is attributed 
to some amino acids, particularly the branched-chain amino acids (leucine, 
isoleucine and valine). GLP-1 may exert its effects by activating its receptor in 
pancreas and enhancing insulin release by β-cells or through its extrapancreatic 
actions. The mechanisms that may justify the aforementioned effects remain 
to be answered, being the mTOR pathway activation a possible key. These 
metabolic effects may have a special interest within the nutritional management 
of Phenylketonuria (PKU), an inborn metabolic disease of phenylalanine (Phe) 
catabolism. Since a Phe restricted diet is the mainstay of PKU treatment, a 
chronic supplementation with a Phe-free amino acid mixture is used. Although 
scientific evidence is scarce, it is hypothesized whether this chronic ingestion 
may modulate glycaemia. 
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acids intake with meals may mitigate glycemic fluctuations [7]. 
The explanation brought forward to elucidate this response is a 
higher insulin secretion, as studied either in humans [8] or animals 
[5]. Out of all essential amino acids, branched-chain amino acids 
(leucine, isoleucine and valine) [9], appear to act as potent insulin 
secretagogues, with special emphasis to leucine [10]. Furthermore, we 
should also keep in mind that nutrients, including amino acids, may 
modulate the synthesis of hormones at the gut level. These are capable 
of modulating glycaemia by boosting insulin release or through 
a direct effect, not closely associated with pancreatic metabolism 
[11]. These substances are called in cretins. The most recognized in 
cretins are Glucose-dependent Insulinotropic Polypeptide (GIP) and 
glucagon-like peptide-1 (GLP-1) [12]. The crosstalk between amino 
acids, glucose, insulin and GLP-1 is illustrated on Figure 1.
Effect of amino acids on glucose metabolism
Several tissues regulate the glucose metabolism after nutrient 
intake. Liver and muscle tissue probably represent the best examples 
[13]. Blood glucose homeostasis results from the balance between 
the rate of plasma glucose appearance and its plasma clearance. The 
most important glucoregulatory hormones are insulin and glucagon 
produced in the pancreas, but also GLP-1 and GIP synthetized in the 
gut [14]. 
A growing body of evidence has demonstrated that a tight blood 
glucose control after a meal may benefit either type 2 diabetic patients 
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Introduction
Glucose homeostasis, in a holistic perspective, is the set of 
responses that maintains the blood glucose levels within the 
physiological range. However, glucose homeostasis goes beyond the 
simple concept of glucose dynamics and implies the activation of 
different organic systems and the recruitment of several hormones 
[1]. Glucose as the prime fuel for some cells and tissues, such as 
brain, is a core molecule for human metabolism [2]. Along with this, 
it is foreseeable that impairment in glycaemia can result in diabetes, 
the paradigm of glucose metabolism disturbances. The long-term 
complications associated with these metabolic imbalances contribute 
to multi-organ injury, highlighting the importance of blood glucose 
management [2].
The effect of amino acids on glucose metabolism has been 
documented for years [3] but the mechanisms underlying this 
interaction are quite complex and not completely understood [4]. 
Amino acid intake may have a pivotal role on glucose homeostasis, 
exhibiting glucose-lowering effects [5,6] suggesting that amino 
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[15] or healthy individuals. Particularly in this healthy group, it 
seems that a cardiovascular disease [16] and type 2 diabetes [17] risk 
reduction may occur. 
Amino acids have been recognized to play a significant role in 
modulating blood glucose concentrations. Many studies have been 
performed in order to investigate in detail the effect of amino acids 
on glucose metabolism, both in humans and animals. Nilsson and 
colleagues (2007) carried out a study in healthy volunteers, where 
the ingestion of a drink containing five-amino acids (leucine, 
isoleucine, valine, lysine and threonine) displayed significantly lower 
blood glucose levels compared to a glucose drink, used as reference. 
Nevertheless, when the number of amino acids was reduced to two 
or three, the same trend was found, although without statistical 
significance [6]. In the same line, Gunnerud and colleagues (2012) 
argued that the ingestion of different protein sources by healthy 
subjects result in different postprandial blood glucose levels. During 
the study, fourteen healthy volunteers underwent a standard meal 
(ham sandwich) with either water or different pre-meal protein 
drinks. These pre-meal protein drinks were based on either whey or 
soy protein isolates, with or without addition of the five-amino acids 
(isoleucine, leucine, lysine, threonine and valine) or the five referred 
amino acids plus arginine. All protein drinks significantly reduced 
blood glucose concentrations compared to the reference meal. In 
addition, meals with whey protein appeared to be more effective in 
decreasing glycaemia than soy protein. Furthermore, this effect of 
reducing blood glucose levels was amplified by the co-ingestion of 
amino acids [18]. 
The study of Bernard and colleagues (2011), performed in 
Sprague-Dawley rats, was designed to investigate the effect of amino 
acid mixtures on the glucose response. The rats were gavaged with 
either glucose, glucose plus an amino acid mixture, glucose plus an 
amino acid mixture with increased leucine concentration or water. 
Blood glucose levels were significantly lower for the two experiments 
supplemented with amino acid mixtures compared to glucose. 
Likewise, the overall glucose area under the curve was lower after 
amino acid mixtures [5]. The same results were found by the study of 
Clemmensen and colleagues (2013), when an oral administration of 
L-arginine was performed to lean and obese mice [19]. 
Effect of amino acids on insulin secretion
Insulin is a key hormone for human metabolism. Absence of 
insulin results in severe metabolic disruptions, since its presence 
is essential for survival. This hormone is produced in and secreted 
from the β-cells of the Langerhans islets at the endocrine pancreas 
[20]. Insulin is secreted in a biphasic way, consisting in one transient 
phase, called the “first phase”, followed by the “second phase” that 
is more prolonged in time [20]. Beyond glucose itself, amino acids 
can also trigger insulin release [2,6,9] especially leucine, isoleucine, 
valine, lysine, threonine and arginine [6,19]. 
The reasons that may explain the insulin release by amino 
acids remain to be answered. Literature has pointed out some 
potential mechanisms, including generation of metabolic coupling 
factors, depolarization of the plasma membrane or enhancement of 
mitochondrial function. The activation of the mammalian target of 
rapamycin (mTOR) pathway in β-cell has been suggested to play an 
important role in this regard [21,22]. 
Effect of amino acids on GLP-1 secretion
Incretins are hormones synthesized in the gut after nutrient 
exposure, with paramount importance in glucose homeostasis 
[23]. The best-studied incretins regarding its influence on glucose 
metabolism are GLP-1 and GIP. GLP-1 is an incretin, produced in 
and secreted from L-cells, located in the gut, mainly in distal ileum 
and colon whereas GIP is produced in and released from gut K-cells 
[24]. They share many common actions directly at the pancreatic 
tissue, although their individual effects in other organs can be 
independent [25]. GLP-1 and GIP, both increase the magnitude of 
insulin release after food ingestion [23], even though GLP-1 appears 
to have a more pronounced incretin effect compared to GIP, mainly 
in type 2 diabetes [26,27]. The two biologically active forms of GLP-
1 are GLP-1 (7-37) amide and GLP-1 (7-36) amide and they are 
produced after post-translational processing of proglucagon. In vivo, 
GLP-1 (7-36) amide is the most abundant GLP-1, with a short half-
life, less than two minutes due to rapid inactivation by the ubiquitous 
enzyme dipeptidyl peptidase IV (DPP-IV) [12].
As with insulin, GLP-1 is secreted in a biphasic manner, 
consisting in a short duration phase (10-15 minutes) followed by a 
more sustained phase (30-60 minutes) [28]. Outside of the pancreas, 
GLP-1 has receptors in multiple organs, such as brain, liver, muscle, 
adipose tissue, stomach and gut, exhibiting pleiotropic actions, which 
include regulation of food intake, gastric emptying and nutrient 
storage [12]. The existence of various target sites of GLP-1 biological 
actions illustrates the complexity of glucose regulation by GLP [29]. 
It is known that amino acids are capable of stimulating GLP-1 
release. The study of Reimann and colleagues (2004) was carried out 
in order to investigate whether glutamine stimulates GLP-1 secretion 
from GLUTag cells in comparison with glucose and the results found 
by this research team showed that the amino acid glutamine acted as 
potent GLP-1 secretagogue [30]. Clemmensen and colleagues (2013) 
reported that an oral administration of L-arginine in lean and diet-
induced obese mice increased plasma levels of insulin and GLP-1. 
They also studied the role of GLP-1 receptor signaling to understand 
its contribute for the expected results and found reduced effect of 
L-arginine to cause insulin secretion and improve glucose tolerance 
in GLP-1 receptor knockout mice [19].
Figure 1: Interplay between amino acids, glucose, insulin and GLP-1. AA: 
Amino Aids; GLP-1: Glucagon-Like Peptide-1.
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The above-referred role of amino acids on GLP-1 secretion 
underpins the fact that some amino acids have a pronounced 
insulinogenic effect that may be partially mediated by incretin system 
activation. 
Metabolic differences between free amino acids and 
whole protein
The molecular structure of proteins is critical for human 
metabolism and there is still debate regarding this matter. Nitrogen 
can be ingested in different molecular forms (free amino acids, 
peptides and proteins), which may affect the efficiency of its utilization 
[31]. The study carried out by Daenzer and colleagues (2001) sought 
to evaluate the effect of a diet containing casein or free amino acid 
mixture with a corresponding amino acid pattern to casein in some 
metabolic parameters. The assay revealed that the rats fed with free 
amino acid mixture had higher urinary nitrogen excretion and lower 
weight gain compared to those given the casein diet, showing that 
free amino acids are not preferentially targeted to protein synthesis. 
The diets were also enriched with labeled leucine and lysine and it 
was found that in rats fed with casein-bound leucine, leucine was 
used more efficiently than in rats fed free leucine, which resulted in 
a greater efficiency of incorporation into liver and plasma proteins. 
Kinetic differences were found regarding lysine, whose incorporation 
into liver proteins was higher in rats fed free amino acids. This study 
concluded that there are differences between intact protein and 
free amino acids regarding its metabolic use and the results cannot 
be extrapolated from one amino acid to another given the fact that 
different amino acids have different sites of catabolism [31]. A more 
recent study of Lacroix and colleagues (2006) was performed in healthy 
volunteers to compare the metabolic fate of different labeled milk 
products (casein, milk soluble protein isolate and total milk protein) 
regarding blood and urinary nitrogen pools. The main findings of this 
study were the higher but temporary hyperaminoacidemia observed 
in the group fed with milk soluble protein isolate in the postmeal 
period and the earlier transference of dietary nitrogen to urea and 
plasma amino acids in the same group as well, followed by casein 
and total milk protein groups. Taking into account these studies, it 
is important to mention the protein composition of milk products 
that consists of two major fractions, whey and casein. The amino acid 
profiles of soluble proteins and caseins are different, which is not the 
only difference between them, because during the digestive process, 
whey proteins are rapidly emptied from the stomach, whereas caseins 
precipitate, which delays amino acids supply to the gut. In addition, 
slowly digested proteins generate better utilization of nitrogen 
compared to rapidly digested proteins, because amino acids are 
released at different rates into blood stream [32].
This segmentation into rapid and slow proteins can be used by 
analogy for free amino acids versus whole protein. 
Taking into consideration that protein and amino acids are well-
known insulin secretagogues, it will be expectable that the magnitude 
of the effect will be different too. 
Metabolic impact of amino acids and its clinical relevance 
– The Phenylketonuria case
The metabolic effects of amino acids ingestion deserve a deep 
analysis considering its relevance for human nutrition and health. 
As described before, amino acid intake seems to be an important 
regulator of glucose metabolism, both in health and disease. Although 
their metabolic effects could be first directed mainly to diabetes 
management, other diseases can also benefit from a deeper knowledge. 
Within the scope of inherited metabolic diseases there is a sub-group 
which includes the metabolic disorders of amino acid catabolism [33]. 
The most common aminoacidopathy is Phenylketonuria (PKU) that 
is characterized by defects in the hepatic enzyme phenylalanine (Phe) 
hydroxylase or in its cofactor, tetrahydrobiopterin (BH4), causing the 
build-up of blood Phe [34]. The mainstay of PKU treatment is a low 
Phe diet, consisting in a natural protein restriction, supplemented 
with Phe-free amino acid mixtures and special low protein foods [35]. 
Adequate energy demands should be satisfied in these patients in order 
to promote amino acid anabolism, preventing the increased nitrogen 
excretion observed especially when amino acids are purely ingested 
[36,37]. Probably as a consequence of the chronic non-compliance of 
this and others nutritional recommendations, nutritional outcomes in 
diet treated patients are not always excellent [38]. Nevertheless, even 
assuming that synthetic diet characteristics may have an important 
impact on nutritional status, this approach has been classified as 
unequivocally successful in preventing the neurological disabilities 
[39]. According to Rocha and colleagues (2012), PKU patients showed 
a lower fasting plasma glucose levels compared to controls, despite 
an absence of differences on basal insulin concentrations or insulin 
resistance [40]. On the other hand, compared to intact milk protein, 
free amino acid mixtures intake, commonly used in PKU treatment, 
resulted in a significantly higher insulinemia peak at 30 minutes [37]. 
Altogether, this raises the question of whether regular ingestion of 
free amino acids in several meals throughout the day can determine 
at least in part some particular glucose behavior in patients with PKU.
Conclusion
Taken together, human and animal studies suggest that amino 
acids influence blood glucose responses. Deeper knowledge about 
this issue may bring insight into the management of PKU patients, 
besides the more immediate impact in the metabolism of individuals 
with diabetes.
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